TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Understanding Disparities in Quitting in African American and White Smokers

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Non-Hispanic African American or non-Hispanic White~* ≥ 18 years of age~* Smoked 3-20 cigarettes per day~* Smoked on \>25 days of the past 30 days~* Functioning telephone~* Interested in quitting smoking~* Interested in taking 3 months of varenicline~* Willing to complete all study visits~Exclusion Criteria:~* Renal impairment~* Evidence or history of clinically significant allergic reactions to varenicline~* A cardiovascular event in the past month Hospitalization in the past 2 months for any cardiovascular disease, including but not limited to:~  * Angina~ * Myocardial infarction~ * Peripheral vascular disease~ * Stroke~* New onset of chest pain or arrhythmia in the past 2 months~* History of alcohol or drug dependency in the past year~* Major depressive disorder in the last year requiring treatment~* History of panic disorder, psychosis, bipolar disorder, or eating disorders~* Use of tobacco products other than cigarettes in past 30 days~* Use of pharmacotherapy in the month prior to enrollment, including prior use of varenicline~* Pregnant, contemplating getting pregnant, or breastfeeding~* Plans to move from Kansas City during the treatment and follow-up phase~* Another household member enrolled in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- African American (AA) Smokers (Type: EXPERIMENTAL): AA smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.
- White Smokers (Type: ACTIVE_COMPARATOR): White smokers received 12 weeks of Varenicline and 6 smoking cessation counseling sessions.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Efficacy and Safety of OC-01 Nasal Spray on Signs and Symptoms of Dry Eye Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~- Have used and/or desired to use an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1~Exclusion Criteria:~* Have had any intraocular surgery (such as cataract surgery) or extraocular surgery in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1.~* Have a history or presence of any ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other clinically significant corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with dry eye disease are allowed.~* Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)~* Have a known hypersensitivity to any of the procedural agents or study drug components~* Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject.

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- OC-01 Low Dose, 0.6 mg/mL (Type: ACTIVE_COMPARATOR): OC-01 (varenicline) nasal spray, 0.6 mg/ML
- OC-01 High Dose, 1.2 mg/mL (Type: ACTIVE_COMPARATOR): OC-01 (varenicline) nasal spray, 1.2 mg/ML
- Placebo (vehicle) nasal spray (Type: PLACEBO_COMPARATOR): Placebo (vehicle) nasal spray

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Etanercept Plus Methotrexate in Early Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of early rheumatoid arthritis.~* Methotrexate (MTX) naive.~* Active early rheumatoid arthritis at the time of enrollment.~Exclusion Criteria:~* Previous or current treatment with etanercept, other tumor necrosis factor-alpha (TNF) inhibitors, or other biologic agents.~* Concurrent treatment with any disease-modifying anti-rheumatoid drugs (DMARD), within 4 weeks before baseline.~* Concurrent treatment with more than 1 non-steroidal anti-inflammatory drug (NSAID) at baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): etanercept + methotrexate; etanercept + methotrexate

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients between the age of 3 and 60 years, inclusive.~* Body weight between 20 kg and 90 kg with no clinical evidence of severe malnutrition.~* Presence of acute uncomplicated P. falciparum mono-infection confirmed by:~  1. Fever, as defined by axillary/tympanic temperature ≥ 37.5°C or oral/rectal temperature ≥ 38°C, or documented history of fever in the previous 24 hours and,~ 2. Positive microscopy of P. falciparum with parasite density between 1,000 and 100,000 asexual parasite count/μl of blood.~* Written informed consent, in accordance with local practice, provided by patient and/or parent/guardian/spouse.~* Ability to swallow oral medication.~Exclusion Criteria:~* Patients with signs and symptoms of severe/complicated malaria requiring parenteral treatment according to the World Health Organization Criteria 2000.~* Mixed Plasmodium infection.~* Severe vomiting or severe diarrhoea.~* Known history or evidence of clinically significant disorders.~* Presence of significant anaemia, as defined by Hb \<8 g/dL.~* Presence of febrile conditions caused by diseases other than malaria.~* Known history of hypersensitivity, allergic or adverse reactions to pyronaridine, lumefantrine or artesunate or other artemisinins.~* Patients with known disturbances of electrolytes balance, e.g., hypokalaemia or hypomagnesaemia.~* Use of any other antimalarial agent within 2 weeks prior to start of the study as evidenced by a positive urine test.~* Female patients of child-bearing potential must be neither pregnant (as demonstrated by a negative pregnancy test) nor lactating, and must be willing to take measures to not become pregnant during the study period.~* Patients taking any drug which is metabolised by the cytochrome enzyme CYP2D6 (flecainide, metoprol, imipramine, amitriptyline, clomipramine).~* Received an investigational drug within the past 4 weeks.~* Known active Hepatitis A IgM (HAV-IgM), Hepatitis B surface antigen. (HBsAg) or Hepatitis C antibody (HCV Ab).~* Known seropositive HIV antibody.~* Liver function tests \[ASAT/ALAT levels\] \>2.5 times the upper limit of normal range.~* Known significant renal impairment as indicated by serum creatinine \>1.4 mg/dL.

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- PA group (Type: EXPERIMENTAL): Pyronaridine artesunate (PA)
- AL group (Type: ACTIVE_COMPARATOR): Arthemether lumefantrine (AL)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed participation in trial F13CD-3760 (NCT01230021)~Exclusion Criteria:~* Known or suspected hypersensitivity to trial product or related products~* Known history of development of inhibitors against FXIII (factor XIII)~* Hereditary or acquired coagulation disorder other than FXIII congenital deficiency~* Platelet count (thrombocytes) less than 50X10e9 / L~* Previous history of autoimmune disorder involving autoantibodies e.g., systemic lupus erythematosus~* Previous history of arterial or venous thromboembolic events e.g., cerebrovascular accident or deep vein thrombosis~* Any disease or condition which, judged by the trial physician, could imply a potential hazard to the subject, interfere with the trial participation or trial outcome including renal and/or liver dysfunction

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- rFXIII 35 IU/kg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Identity Project

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between 18-26 years of age~* Left homelessness within the last 3 years (youth living in supportive housing contexts (e.g., transitional housing) will be considered to have left homelessness)~* Currently not homeless (youth in supportive or transitional housing are eligible)~* A concerted effort will be made to recruit young people facing additional identity-related challenges like newcomer and racialized youth, Indigenous youth, and youth who belong to the LGBTQ2S community.~Exclusion Criteria:~* Not fluent in English~* Cannot provide informed consent~* Cannot commit to attending two full-day workshops and four half-day group coaching sessions over the course of six weeks (missing more than one workshop and two coaching sessions will disqualify participants from the study)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 26 Years
- Healthy Volunteers: t

Study Arms:
- Immediate dk Leadership Intervention (Type: EXPERIMENTAL): Participants allocated to the immediate intervention group are assessed for study outcomes immediately prior to the 6-week dk Leadership intervention and immediately after the intervention.~Outcomes measured immediately post-intervention are compared with participants who have not received the intervention during the 6 weeks.~After the delayed intervention group takes the intervention, the two groups are joined into a single arm.
- Delayed dk Leadership Intervention (Type: PLACEBO_COMPARATOR): Participants allocated to this arm receive 6 weeks of no intervention. Outcomes are measured immediately before and immediately after the 6 week period. The change in outcomes are compared with participants who have received the intervention during the 6 week period.~This group then receives the same dk Leadership intervention; after this point, the two groups are joined into a single arm for subsequent analyses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multi-Center Trial of Botox for Severe Urge Urinary Incontinence

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Female subjects 21-90 years of age~* subjects has urinary incontinence on 3 day bladder diary~* subject has severe incontinence~* urine dipstick or urine culture negative for urinary tract infection~* cystometrogram without stress urinary leakage~* must have failed at least one anti-cholinergic medication~* negative urine pregnancy test on day of administration of study medication~Exclusion Criteria:~* history of carcinoma of the bladder~* presence of foreign body in the bladder, cystitis or other correctable etiology for Urge Urinary Incontinance~* gross fecal incontinence~* known allergy to sulfa or ciprofloxacin or to lidocaine~* any medical condition that may put the subject at increased risk with exposure to Botox~* females who are pregnant, breast-feeding, or planning a pregnancy during the study or who are of child-bearing potential~* known allergy to any of the components in the study medication~* prior documented resistance to Botox~* evidence of recent alcohol or drug abuse~* concurrent participation in another investigational drug or device study within 30 days

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): Placebo
- 2 (Type: EXPERIMENTAL): Botox

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study to Compare the Efficacy and Safety of Rituximab Biosimilar HLX01 and Rituximab in Combination With CHOP, in Previously Untreated Subjects With CD20+ DLBCL

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Untreated CD20-positive DLBCL confirmed.~* IPI score of 1 to 2, Stage I \~ IV, Score 0 needs to accompanied by bulky disease, which is defined as the presence of a tumor mass with a diameter of more than 7.5 cm.~* ECOG performance status of 0 to 2.~* More than 6 months life expectancy.~* At least one measurable lesion: For nodal tumor mass, more than 1.5 cm in the long axis and more than 1.0 cm in the short axis; For extranodal tumor mass, more than 1.0 cm in the long axis.~* 18 years to 70 years; Male or female patients.~Exclusion Criteria:~* Known allergic reactions against human or murine monoclonal antibody, murine products, or foreign proteins.~* Known allergic reactions against any component of CHOP regimen.~* Previous treatment for NHL, including chemotherapy, immunotherapy, partial radiotherapy for lymphoma, monoclonal antibody therapy or surgical treatment (excluding lymph node biopsies and surgical resection for non-lymphoma lesions).~* History of cytotoxic drugs treatment or anti-CD20 monoclonal antibody treatment for other disease (e.g., rheumatoid arthritis).~* Prior use of any monoclonal antibody within 3 months.~* Primary central nervous system(CNS) lymphoma, secondary CNS involvement, grey zone lymphoma (GZL) between burkitt and DLBCL, primary effusion lymphoma, plasmablastic lymphoma, primary cutaneous DLBCL, anaplastic lymphoma kinase(ALK) positive DLBCL or transformed lymphoma.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HLX01 (Type: EXPERIMENTAL): 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)
- Rituximab (Type: ACTIVE_COMPARATOR): 375mg/m2 iv q3w, 6 cycles(each cycle is 3 weeks)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety & Efficacy Study of Quetiapine Fumarate (SEROQUEL®) vs. Placebo & Active Control in Generalized Anxiety Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient has a documented clinical diagnosis of Generalized Anxiety Disorder.~* Be able to understand and comply with the requirements of the study.~* Able to understand and provide written informed consent~Exclusion Criteria:~* Patients (female) must not be pregnant or lactating~* Current or past diagnosis of stroke or transient ischemic attack (TIA).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dapagliflozin on Insulin Secretion and Insulin Sensitivity in Patients With Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients both sexes~* Age between 30 and 60 years~* Diagnosis of prediabetes according ADA criteria (fasting blood glucose levels between 100-126 mg/dl; postprandial blood glucose levels after an oral glucose tolerance test with 75 of oral glucose between 140-199 mg/dl; or glycosylated hemoglobin between 5.7-6.4%)~* Informed consent signed~Exclusion Criteria:~* Women with confirmed or suspected pregnancy~* Women under lactation and/or puerperium~* Hypersensibility to ingredients of intervention~* Physical impossibility for taking pills~* Known uncontrolled renal, hepatic, heart or thyroid diseased~* Diabetes diagnosis~* Previous treatment for glucose~* Body Mass Index ≥35 kg/m2~* Triglycerides ≥500 mg/dL~* Total cholesterol ≥240 mg/dL~* Low density lipoprotein (c-LDL) ≥190 mg/dL~* Blood Pressure ≥140/90 mmHg

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Dapagliflozin (Type: EXPERIMENTAL): Dapagliflozin capsules, 10 mg, one per day before breakfast during 12 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsules, one per day before breakfast during 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of mRNA-1944 in Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 18 and ≤ 50 years of age~* Weight of 50 to 100 kg, inclusive~* In good general health as determined by medical history, clinical laboratory assessments, ECG results, vital sign measurements, and physical examination findings at screening~* Has access to consistent and reliable means of contact and agrees to stay in contact with the study site for the duration of the study~Exclusion Criteria:~* Any acute or chronic clinically significant disease, as determined by physical examination or laboratory screening tests~* Elevated liver function tests or safety laboratory test results~* Positive screening test for the presence of anti-CHIKV IgG~* Administration of another investigational study involving any investigational product within 60 days or 5 half-lives, whichever is longer~* Has received any live attenuated or inactive vaccines within 4 weeks prior to check-in, or plans to receive any vaccine during the study~* Known or suspected immune-mediated disease or immunosuppressive condition (including lymphoproliferative disorders)~* Any neurologic disorder~* History of idiopathic urticaria~* Any bleeding disorder that is considered a contraindication to study drug infusion or blood collection~* Receipt of immunoglobulins, a monoclonal antibody or any blood products within the preceding 6 months~* Any acute illness at the time of enrollment~* A positive test result for drugs of abuse~* A positive test result for hepatitis B surface antigen, hepatitis C virus antibody, or human immunodeficiency virus type 1 or 2 antibodies~* A history of active cancer (malignancy) in the last 3 years~* Donation of ≥ 450 mL blood or blood products within 30 days of study drug infusion

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- mRNA-1944 (Type: EXPERIMENTAL): Escalating dose levels
- Placebo (Type: PLACEBO_COMPARATOR): Saline

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Fatty Acid Supplementation in Children With ASD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Age 2-6 years old~* ASD diagnosis at Nationwide Children's Hospital within the prior 6 months~* ADOS-2 score in autism (severe) range~* English is primary language~Exclusion Criteria:~* Fatty acid supplementation in the past 6 months~* Consumes fatty fish more than 3 times per week~* Still breastfeeding or formula feeding~* Quadriparesis~* Deafness~* Blindness~* Seizure disorder diagnosis~* Autoimmune disorder including Type 1 Diabetes, Fragile X, Rett, Angleman Syndromes, Tuberous Schlerosis~* Feeding problems precluding consumption of the supplement~* Ingredient allergy (canola, fish, or borage seed)~* Planned surgeries scheduled within the time frame of trial participation

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- LCPUFA Oil Supplement, Low Dose (Type: EXPERIMENTAL): 25 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- LCPUFA Oil Supplement, Medium Dose (Type: EXPERIMENTAL): 50 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- LCPUFA Oil Supplement, High Dose (Type: EXPERIMENTAL): 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days
- Canola Oil (Type: PLACEBO_COMPARATOR): Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete